Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 15/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7646895 | 0.92 | CYP1B1 (0.56) | CYP1B1ALDH1A1POLBRXFP1KDM4E | |
| SCHEMBL20735017 | 0.87 | ALDH1A1 (0.52) | CYP1B1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL20735085 | 0.84 | ALDH1A1 (0.50) | CYP1B1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL7646060 | 0.83 | KEAP1 (0.57) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL20735248 | 0.83 | ALDH1A1 (0.49) | CYP1B1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL5520058 | 0.83 | ALDH1A1 (0.57) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL20735163 | 0.83 | ALDH1A1 (0.49) | CYP1B1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL20735196 | 0.83 | ALDH1A1 (0.49) | CYP1B1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL20735199 | 0.83 | ALDH1A1 (0.49) | CYP1B1ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL29141594 | 0.83 | CYP1B1 (0.47) | CYP1B1ALDH1A1POLBRXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358362-B2 | Method for the production of terylene-3,4:11,12-tetracarboxydiimides by direct synthesis | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-15 | — | — | US | disclosed |
| US-20070155968-A1 | Method for the production of terylene-3,4:11,12-tetracarboxydiimides by direct synthesis | BASF AKTIENGESELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155968-A1 | Method for the production of terylene-3,4:11,12-tetracarboxydiimides by direct synthesis | HACL2, HRH3, HCN2 | CYP1B1 748/4885ALDH1A1 3629/4885POLB 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.